Core Insights - Rakovina Therapeutics is advancing its AI-derived PARP-1 inhibitor program, showcasing progress at the 2025 Society for Neuro-Oncology Annual Meeting [1][5] - The company is utilizing AI methods to discover and characterize novel PARP1-selective small-molecule drug candidates that penetrate the central nervous system (CNS) [2][4] Research and Development - A scientific poster titled "Discovery and development of novel CNS-penetrating PARP1-selective inhibitors" was presented, highlighting collaboration with the Vancouver Prostate Centre and the University of British Columbia [2] - The research employs Deep Docking™ and generative-AI computational approaches to screen large chemical libraries for compounds with selective inhibition of PARP1 and favorable drug-like properties [3][4] Results and Data - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and promising in vitro metabolic stability and pharmacokinetic profiles [4] - The presentation included comparisons of ADME and pharmacokinetic data from synthesized compounds against existing PARP inhibitors and next-generation benchmarks [4] Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]

Core Insights - Rakovina Therapeutics presented a second scientific abstract at the 2025 Society for Neuro-Oncology Annual Meeting, focusing on AI-enabled drug discovery for cancer therapies [1][5] - The research highlights the development of novel CNS-penetrating PARP1-selective inhibitors through collaboration with the Vancouver Prostate Centre and the University of British Columbia [2][5] Group 1: Research and Development - The poster presentation detailed the application of AI methods, specifically Deep Docking™ and generative-AI computational approaches, to screen chemical libraries for PARP1-selective small-molecule drug candidates [3][4] - Hundreds of prioritized compounds have been synthesized and evaluated, with a subset showing PARP1-selective activity and favorable pharmacokinetic profiles [4][5] Group 2: Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, utilizing unique technologies for targeting DNA-damage response powered by AI [6] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]

Core Insights - Rakovina Therapeutics has announced significant advancements in its AI-enabled ATR program, showcasing novel ATR/mTOR dual inhibitors designed for brain penetration and efficacy in PTEN-deficient tumor models [1][2][10] Group 1: Discovery and Development - The company presented a poster at the 2025 Society for Neuro-Oncology Annual Meeting detailing the discovery of CNS-penetrating ATR inhibitors that combine ATR and mTOR inhibition, targeting PTEN-deficient tumors [2][4] - The lead molecules were specifically engineered to cross the blood-brain barrier, making them potentially effective against primary brain cancers and those with a high risk of brain metastasis [2][4] Group 2: Efficacy and Mechanism - The AI-discovered ATR/mTOR inhibitors demonstrated over 50% ATR inhibition at 1 µM, showing comparable or superior potency to existing ATR inhibitors like ceralasertib, tuvusertib, and elimusertib [3][7] - These compounds are designed to co-target ATR and mTOR pathways, which are critical for the survival of PTEN-deficient tumors, potentially overcoming resistance mechanisms associated with ATR-only therapies [4][6] Group 3: Clinical Relevance and Future Directions - The pharmacokinetic profiling indicated favorable tolerability and measurable CNS exposure in mice, supporting further evaluation in brain tumor models [8][9] - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials, leveraging AI technologies for rapid drug candidate optimization [11][12]

Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-enabled drug discovery and will participate in the 9th Annual DNA Damage Response (DDR) Inhibitors Summit in January 2026 [1][2] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on innovative cancer treatments, utilizing unique technologies for targeting DNA-damage response powered by AI [6] - The company has developed a pipeline of distinctive DNA-damage response inhibitors, aiming to advance drug candidates into human clinical trials in collaboration with pharmaceutical partners [7] Event Participation - Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina, will present on "Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics" at the summit [3] - In addition to his presentation, Prof. Daugaard will engage in discussions on empowering academic entrepreneurs and aligning scientific vision with investment strategy [4] Industry Context - The DDR field is experiencing significant advancements due to new discoveries in DNA damage response biology and the integration of AI into early drug discovery [5] - The summit will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, emphasizing translational strategies for clinical impact [2]

Core Insights - Rakovina Therapeutics is set to present new data at the Society for Neuro-Oncology Annual Meeting, focusing on AI-driven cancer therapies targeting DNA-damage response inhibitors for brain cancers [1][2]. Presentation Details - The company will showcase two posters on November 21, 2025, detailing the discovery and development of CNS-penetrating ATR and PARP1-selective inhibitors [3][4]. - The first poster discusses the kt-5000AI ATR inhibitor program, developed with Variational AI, highlighting the discovery of potent ATR inhibitors effective against treatment-resistant tumors [3]. - The second poster covers the kt-2000AI PARP inhibitor program, utilizing the Deep Docking™ platform for virtual screening of billions of compounds to identify CNS-penetrant inhibitors [4]. Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [7][8]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [8].

Core Insights - Rakovina Therapeutics presented new data on its AI-driven kt-5000AI drug discovery program for ATR inhibitors at the AACR-NCI-EORTC conference, highlighting promising results for cancer therapy targeting CNS penetration [1][2][3] Company Developments - The collaboration with Variational AI utilized the Enki™ generative AI platform to identify novel small-molecule candidates for CNS-penetrant ATR inhibition, with multiple lead compounds achieving the desired profile [2][3] - Rakovina's kt-5000AI program is advancing next-generation ATR inhibitors that have confirmed CNS exposure, potentially benefiting patients with primary brain tumors and brain metastases [3][5] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6] Scientific Findings - In cell-based assays, lead compounds demonstrated over 50% inhibition of ATR activity below 200 nM, with potency exceeding reference compounds such as ceralasertib, tuvusertib, and elimusertib [7] - In vivo pharmacokinetic studies showed measurable drug concentrations in plasma and brain tissue after intraperitoneal dosing at 5 mg/kg, indicating CNS penetration and good tolerability after single-dose administration [7]

VANCOUVER, British Columbia, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new preclinical data from its ATR inhibitor program will be presented in a poster session at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 22-26 at the Hynes Convention Center Boston, Massac ...

Core Insights - Rakovina Therapeutics Inc. is participating in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City, where key executives will present the company's R&D pipeline and corporate strategy [1][2][4]. Company Overview - Rakovina Therapeutics is a biopharmaceutical company focused on developing innovative cancer treatments using AI-powered drug discovery technologies, specifically the Deep-Docking™ and Enki™ platforms [6][7]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [7]. Recent Corporate Highlights - The company has achieved significant milestones in 2025, including presenting new preclinical data at the AACR Annual Meeting and obtaining DTC eligibility to enhance market accessibility for U.S. investors [3][8]. - Rakovina has advanced its KT-5000AI program, yielding potent ATR inhibitor candidates through AI-enabled screening [8]. - A non-binding Letter of Intent has been announced with Saudi-based NanoPalm Ltd. to form a joint venture that combines AI-discovered oncology therapeutics with patterned lipid nanoparticle delivery systems [8].

Core Viewpoint - Rakovina Therapeutics Inc. reported its financial results for Q2 2025, highlighting advancements in AI-powered drug discovery for cancer therapies and recent corporate developments [1]. Financial Highlights - Cash and cash equivalents as of June 30, 2025, were CAD 1.88 million, an increase from CAD 1.31 million as of December 31, 2024 [5]. - Working capital improved to CAD 622,851 from CAD 321,442 [5]. - Total assets increased to CAD 6.55 million from CAD 6.24 million [5]. - Total liabilities rose significantly to CAD 3.34 million from CAD 1.94 million [5]. - The net loss for Q2 2025 was CAD 2.92 million, compared to a loss of CAD 820,720 in Q2 2024 [8]. Research and Development Expenses - R&D expenses for Q2 2025 were CAD 1.61 million, a substantial increase from CAD 479,785 in Q2 2024 [8]. - General and administrative expenses were CAD 1.21 million, up from CAD 276,183 [8]. Corporate Developments - The company closed a non-brokered private placement on June 6, 2025, raising approximately CAD 3.56 million [7]. - A reverse share consolidation was implemented on June 24, 2025, at a ratio of 1-for-10, resulting in 21,148,039 common shares outstanding as of June 30, 2025 [7]. - On June 30, 2025, the company announced intentions to amend certain outstanding warrants and convertible debentures totaling CAD 1.45 million, pending TSXV approval [7]. - A warrant exercise incentive program was announced on July 24, 2025, to encourage early exercise of certain outstanding warrants [7]. Stock Options - The company granted 540,000 stock options post-consolidation to various stakeholders, exercisable at CAD 0.70 per share with a vesting period of six months over three years [7].

Core Insights - Rakovina Therapeutics Inc. is advancing cancer therapies through AI-powered drug discovery and has announced that its Chief Scientific Officer, Dr. Mads Daugaard, will present at the 13th Tuscany Retreat on Cancer Research and Apoptosis [1][2] Company Overview - Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments, utilizing unique technologies for targeting the DNA-damage response powered by AI through proprietary platforms like Deep-Docking™ and Enki™ [4][5] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners, establishing a pipeline of distinctive DNA-damage response inhibitors [5] Research and Collaboration - Dr. Daugaard's presentation will cover ongoing research programs at the Vancouver Prostate Centre, including collaborative development programs with Rakovina Therapeutics, highlighting the company's commitment to advancing therapies targeting the DNA-damage response [2][3] - The Tuscany Retreat serves as a platform for collaboration and exchange of ideas among established leaders and the next generation of cancer researchers, emphasizing the importance of such forums in translating discoveries into patient benefits [3][4]